2023 World Conference on Lung Cancer (Posters)-P2.05. Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials

P2.05. Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials - PDF(Slides)

Back to course

Pdf Summary

This study investigated the impact of EGFR co-mutation patterns on the efficacy of immune checkpoint inhibitors (ICIs) in EGFR-mutated non-small cell lung cancer (NSCLC) patients. The researchers analyzed data from the OAK and POPLAR trials, which included advanced NSCLC patients treated with atezolizumab or docetaxel. Out of the 56 EGFR-mutated patients treated with atezolizumab, distinct EGFR co-mutation patterns were found to have different effects on the efficacy of ICIs.<br /><br />The results showed that patients with co-mutations in EGFR and LRP1B or FAT3 had better outcomes with ICIs. They had higher objective response rates (ORR), overall survival (OS), and progression-free survival (PFS) compared to patients with only EGFR single mutation (SM). Specifically, patients with EGFR&LRP1B co-mutation had a significantly higher ORR, OS, and PFS compared to those with EGFR SM. Similarly, patients with EGFR&FAT3 co-mutation had increased ORR and significantly prolonged PFS.<br /><br />Interestingly, both EGFR&LRP1B and EGFR&FAT3 co-mutation patients had higher tumor mutational burden (bTMB) compared to EGFR SM patients, while PD-L1 expression levels were similar.<br /><br />In conclusion, this study suggests that different EGFR co-mutation patterns have distinct effects on the efficacy of ICIs in EGFR-mutated NSCLC patients. Patients with co-mutations in EGFR and LRP1B or FAT3 seem to benefit more from ICIs. These findings highlight the importance of considering co-mutation patterns in personalized treatment decisions for EGFR-mutated NSCLC patients receiving ICIs.

Asset Subtitle

Wengang Zhang

Meta Tag

Speaker Wengang Zhang

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

EGFR co-mutation patterns

immune checkpoint inhibitors

EGFR-mutated non-small cell lung cancer

NSCLC patients

OAK trial

POPLAR trial

atezolizumab

docetaxel

LRP1B co-mutation

FAT3 co-mutation